Back to Market News

MedservRegis plc – Details of New Bond Issue

Jonathan Falzon

October 21, 2025

21 October, 2025
7 min read
21 October, 2025
7 min read

Following last week's article detailing the performance of the S&P 500 index in 2025, it is worth devoting time to review the developments across the European equity markers in my last article of the year.

On 21 October 2025, MedservRegis plc published a Prospectus following regulatory approval for the admissibility to listing on the Official List of the Malta Stock Exchange of up to €25 million in a mix of 5.50% euro-denominated unsecured bonds and 6.50% US dollar-denominated unsecured bonds maturing between 2031 and 2036. The salient details of the new bond issue are as follows:

Coupon:

5.50% for the euro-denominated bonds

6.50% for the US dollar-denominated bonds

Amount Offered:

Up to €25 million (nominal)

Issue Price:

100% (par)

Maturity:

The bonds will mature on 30 June 2036. However, MedservRegis plc reserves the right to redeem any or all of the bonds on any date between 30 June 2031 and 30 June 2036, by giving bondholders at least 30 days’ notice.

Interest Payment Date:

Annually on 30 June (the first interest payment date is on 30 June 2026 and will entail the pro rata interest payable for the period between 26 November 2025 to 30 June 2026)

Status of the Bonds:

The bonds will constitute the general, direct, unsecured, and unconditional obligations of the Issuer and will at all times rank pari passu, without any priority or preference among themselves and with other outstanding and unsecured debt of the issuer, save for such exceptions as may be provided by applicable law.

Use of Proceeds:

The proceeds from the bond issue will be used for the part redemption and cancellation, by way of an exchangeable bonds transfer, of the €22 million 4.50% euro-denominated unsecured bonds and the USD8 million 5.75% US dollar-denominated unsecured bonds, both redeemable on 5 February 2026.

Plan of Distribution:

The entire €25 million in nominal value of the bonds has been reserved for the holders of the 4.50% euro-denominated unsecured bonds and the 5.75% US dollar-denominated unsecured bonds, both redeemable on 5 February 2026.

Any remaining balance of bonds not subscribed to by the preferred applicants may be made available to Authorised Financial Intermediaries through an Intermediaries’ Offer.

Offer Period:

24 October 2025 to 7 November 2025 at 13:00 hours.

An Intermediaries’ Offer will take place on 13 November 2025 if required.

Minimum Subscription Amount:

€5,000 (nominal) and in multiples of €5,000 thereafter

USD5,000 (nominal) and in multiples of USD5,000 thereafter

Listing:

Official List of the Malta Stock Exchange

Expected Listing Date:

26 November 2025

Downloads:

Summary dated 20 October 2025

Registration Document dated 20 October 2025

Securities Note dated 20 October 2025

Fact Sheet dated 22 October 2025

 

Disclaimer:

This webpage has been prepared based on the Prospectus dated 20 October 2025 issued by MedservRegis plc and no representations or guarantees are made by Rizzo, Farrugia & Co. (Stockbrokers) Ltd with respect to the accuracy of the data. This webpage is for information purposes only. It is NOT intended to be and should NOT be construed as an offer or solicitation to acquire or dispose of any of the securities or issues mentioned herein. Rizzo, Farrugia & Co. (Stockbrokers) Ltd accepts NO responsibility or liability whatsoever for any expense, loss or damages arising out of, or in any way connected with, the use of all or any part of this webpage.

Investors wishing to acquire the Bonds should read the Prospectus before making any investment decision in order to fully understand the potential risks and rewards associated with an investment in the Bonds. A copy of the Prospectus is available on Rizzo, Farrugia & Co. (Stockbrokers) Limited’s website. Prospective investors are urged to consult their financial advisers as to the suitability or otherwise of acquiring such Bonds. The value of the investment and the income therefrom may go down as well as up and investors may lose some or all of the money invested.

Rizzo, Farrugia & Co. (Stockbrokers) Limited is acting as Sponsor, Manager & Registrar to MedservRegis plc.

This advertisment has been issued by Rizzo, Farrugia & Co. (Stockbrokers) Limited which is a company licensed to undertake investment services in Malta by the MFSA under the Investment Services Act, Cap. 370 of the Laws of Malta and a member of the Malta Stock Exchange. The Company’s registered address is at Airways House, Fourth Floor, High Street, Sliema SLM 1551, Malta.

The article contains public information only and is published solely for informational purposes. It should not be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in this article. Rizzo, Farrugia & Co. (Stockbrokers) Ltd (“Rizzo Farrugia”) is under no obligation to update or keep current the information contained herein. Since the buying and selling of securities by any person is dependent on that person’s financial situation and an assessment of the suitability and appropriateness of the proposed transaction, no person should act upon any recommendation in this article without first obtaining investment advice. Rizzo Farrugia, its directors, the author of this article, other employees or clients may have or have had interests in the securities referred to herein and may at any time make purchases and/or sales in them as principal or agent. Furthermore, Rizzo Farrugia may have or have had a relationship with or may provide or has provided other services of a corporate nature to companies herein mentioned. Stock markets are volatile and subject to fluctuations which cannot be reasonably foreseen. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security mentioned in this article. Neither Rizzo Farrugia, nor any of its directors or employees accepts any liability for any loss or damage arising out of the use of all or any part of this article. Additional information can be made available upon request from Rizzo, Farrugia & Co. (Stockbrokers) Ltd., Airways House, Fourth Floor, High Street, Sliema SLM 1551. Telephone: +356 2258 3000; Email: info@rizzofarrugia.com; Website: www.rizzofarrugia.com © 2021 Rizzo, Farrugia & Co. (Stockbrokers) Ltd. All rights reserved. This article may not be reproduced or redistributed, in whole or in part, without the written permission of Rizzo Farrugia. Moreover, Rizzo Farrugia accepts no liability whatsoever for the actions of third parties in this respect.

This article was produced by Edward Rizzo, Director at Rizzo Farrugia, which is a company licensed to undertake investment services in Malta by the MFSA under the Investment Services Act, Cap. 370 of the Laws of Malta and a member of the Malta Stock Exchange. The company’s registered address is at Airways House, Fourth Floor, High Street, Sliema SLM 1551, Malta.

The article contains public information only and is published solely for informational purposes. It should not be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in this article. Rizzo, Farrugia & Co. (Stockbrokers) Ltd (“Rizzo Farrugia”) is under no obligation to update or keep current the information contained herein. Since the buying and selling of securities by any person is dependent on that person’s financial situation and an assessment of the suitability and appropriateness of the proposed transaction, no person should act upon any recommendation in this article without first obtaining investment advice. Rizzo Farrugia, its directors, the author of this article, other employees or clients may have or have had interests in the securities referred to herein and may at any time make purchases and/or sales in them as principal or agent. Furthermore, Rizzo Farrugia may have or have had a relationship with or may provide or has provided other services of a corporate nature to companies herein mentioned. Stock markets are volatile and subject to fluctuations which cannot be reasonably foreseen. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security mentioned in this article. Neither Rizzo Farrugia, nor any of its directors or employees accepts any liability for any loss or damage arising out of the use of all or any part of this article. Additional information can be made available upon request from Rizzo, Farrugia & Co. (Stockbrokers) Ltd., Airways House, Fourth Floor, High Street, Sliema SLM 1551. Telephone: +356 2258 3000; Email: info@rizzofarrugia.com; Website: www.rizzofarrugia.com © 2021 Rizzo, Farrugia & Co. (Stockbrokers) Ltd. All rights reserved. This article may not be reproduced or redistributed, in whole or in part, without the written permission of Rizzo Farrugia. Moreover, Rizzo Farrugia accepts no liability whatsoever for the actions of third parties in this respect.

This article was produced by Edward Rizzo, Director at Rizzo Farrugia, which is a company licensed to undertake investment services in Malta by the MFSA under the Investment Services Act, Cap. 370 of the Laws of Malta and a member of the Malta Stock Exchange. The company’s registered address is at Airways House, Fourth Floor, High Street, Sliema SLM 1551, Malta.

On 21 October 2025, MedservRegis plc published a Prospectus following regulatory approval for the admissibility to listing on the Official List of the Malta Stock Exchange of up to €25 million in a mix of 5.50% euro-denominated unsecured bonds and 6.50% US dollar-denominated unsecured bonds maturing between 2031 and 2036. The salient details of the new bond issue are as follows:

Coupon:

5.50% for the euro-denominated bonds

6.50% for the US dollar-denominated bonds

Amount Offered:

Up to €25 million (nominal)

Issue Price:

100% (par)

Maturity:

The bonds will mature on 30 June 2036. However, MedservRegis plc reserves the right to redeem any or all of the bonds on any date between 30 June 2031 and 30 June 2036, by giving bondholders at least 30 days’ notice.

Interest Payment Date:

Annually on 30 June (the first interest payment date is on 30 June 2026 and will entail the pro rata interest payable for the period between 26 November 2025 to 30 June 2026)

Status of the Bonds:

The bonds will constitute the general, direct, unsecured, and unconditional obligations of the Issuer and will at all times rank pari passu, without any priority or preference among themselves and with other outstanding and unsecured debt of the issuer, save for such exceptions as may be provided by applicable law.

Use of Proceeds:

The proceeds from the bond issue will be used for the part redemption and cancellation, by way of an exchangeable bonds transfer, of the €22 million 4.50% euro-denominated unsecured bonds and the USD8 million 5.75% US dollar-denominated unsecured bonds, both redeemable on 5 February 2026.

Plan of Distribution:

The entire €25 million in nominal value of the bonds has been reserved for the holders of the 4.50% euro-denominated unsecured bonds and the 5.75% US dollar-denominated unsecured bonds, both redeemable on 5 February 2026.

Any remaining balance of bonds not subscribed to by the preferred applicants may be made available to Authorised Financial Intermediaries through an Intermediaries’ Offer.

Offer Period:

24 October 2025 to 7 November 2025 at 13:00 hours.

An Intermediaries’ Offer will take place on 13 November 2025 if required.

Minimum Subscription Amount:

€5,000 (nominal) and in multiples of €5,000 thereafter

USD5,000 (nominal) and in multiples of USD5,000 thereafter

Listing:

Official List of the Malta Stock Exchange

Expected Listing Date:

26 November 2025

Downloads:

Summary dated 20 October 2025

Registration Document dated 20 October 2025

Securities Note dated 20 October 2025

Fact Sheet dated 22 October 2025

 

Disclaimer:

This webpage has been prepared based on the Prospectus dated 20 October 2025 issued by MedservRegis plc and no representations or guarantees are made by Rizzo, Farrugia & Co. (Stockbrokers) Ltd with respect to the accuracy of the data. This webpage is for information purposes only. It is NOT intended to be and should NOT be construed as an offer or solicitation to acquire or dispose of any of the securities or issues mentioned herein. Rizzo, Farrugia & Co. (Stockbrokers) Ltd accepts NO responsibility or liability whatsoever for any expense, loss or damages arising out of, or in any way connected with, the use of all or any part of this webpage.

Investors wishing to acquire the Bonds should read the Prospectus before making any investment decision in order to fully understand the potential risks and rewards associated with an investment in the Bonds. A copy of the Prospectus is available on Rizzo, Farrugia & Co. (Stockbrokers) Limited’s website. Prospective investors are urged to consult their financial advisers as to the suitability or otherwise of acquiring such Bonds. The value of the investment and the income therefrom may go down as well as up and investors may lose some or all of the money invested.

Rizzo, Farrugia & Co. (Stockbrokers) Limited is acting as Sponsor, Manager & Registrar to MedservRegis plc.

This advertisment has been issued by Rizzo, Farrugia & Co. (Stockbrokers) Limited which is a company licensed to undertake investment services in Malta by the MFSA under the Investment Services Act, Cap. 370 of the Laws of Malta and a member of the Malta Stock Exchange. The Company’s registered address is at Airways House, Fourth Floor, High Street, Sliema SLM 1551, Malta.